Related Experiment Video
Updated: Aug 9, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Administration of dexamethasone induces proteinuria of glomerular origin in mice
1Department of Pathology, Tri-Service General Hospital, Taipei, Taiwan, ROC.
Abstract:
The administration of glucocorticoids has been reported to exacerbate proteinuria in a few patients with glomerulonephritis. This effect has not been well recognized, and the pathogenetic mechanism responsible for this phenomenon remains to be clarified. In this study, we observed that a high daily oral dose (0.5 mg/kg body weight) of dexamethasone was capable of inducing overt proteinuria in mice, beginning on day 5 and persisting for a 19-day duration. One fourth of mice also intermittently presented with slight hematuria beginning on day 12. Renal lesions in the dexamethasone-treated mice, which were killed on day 23, were characterized by mild mesangial expansion, segmental or global hyalinosis/sclerosis in deep cortical glomeruli, and focal tubular changes. No glomerular inflammatory cell infiltration or proliferative lesion was noted in any of the mice. Ultrastructural features of glomeruli included mesangial widening characterized by either an increase of mesangial matrix, dilated mesangial channels filled with slightly electron-dense material or mesangial lysis-like appearance showing intracytoplasmic microcysts filled with electron-lucent material, and evidence to support injury of endothelial cells, erythrocytes, and podocytes. An immunofluorescence study revealed enhanced glomerular deposition of IgG, IgA, IgM, and fibrinogen (P < 0.001, compared with normal control mice), but no glomerular C3 deposition was identified in any of the dexamethasone-treated mice. Charge analysis showed no impairment in anionic property of glomerular tufts in the dexamethasone-treated mice. In addition, the dexamethasone-induced proteinuria was greatly attenuated by treatment with a low molecular weight heparin, although it was not reduced by an angiotensin-converting enzyme inhibitor. Data from these experiments suggest that a large dose of glucocorticoids is potentially nephrotoxic. Alteration of a size-dependent permeability may predominantly contribute to the dexamethasone-induced proteinuria. However, the effect of glomerular hyperfiltration may be only partially involved in the pathogenesis of this dexamethasone-induced glomerulopathy in mice.
Insights
High-dose dexamethasone (glucocorticoid) causes proteinuria and kidney damage in mice. This nephrotoxicity appears linked to altered size-dependent permeability, not glomerular hyperfiltration.
Area of Science:
- Nephrology
- Pharmacology
- Pathology
Background:
- Glucocorticoids can worsen proteinuria in some glomerulonephritis patients.
- The mechanism behind glucocorticoid-induced proteinuria is not well understood.
Purpose of the Study:
- To investigate the effects of high-dose dexamethasone on mouse kidneys.
- To clarify the pathogenetic mechanisms of dexamethasone-induced proteinuria.
Main Methods:
- Administered high-dose dexamethasone (0.5 mg/kg/day) orally to mice for 23 days.
- Assessed proteinuria, hematuria, renal histology, ultrastructural changes, immunofluorescence, and glomerular charge.
- Tested the effects of heparin and angiotensin-converting enzyme inhibitors on proteinuria.
Main Results:
- Dexamethasone induced significant proteinuria and mild renal lesions, including mesangial expansion and tubular changes.
- Ultrastructural analysis revealed mesangial widening, endothelial, erythrocyte, and podocyte injury.
- Enhanced glomerular deposition of IgG, IgA, IgM, and fibrinogen was observed, but no C3 deposition.
Conclusions:
- High-dose glucocorticoids can be nephrotoxic, causing proteinuria predominantly through altered size-dependent permeability.
- Heparin attenuated proteinuria, while ACE inhibitors did not, suggesting specific pathways involved.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management

